#NewAseBioMember | “AseBio represents the meeting point of Spain’s biotechnology ecosystem”

AseBio. What does your company bring to the table, and what is its main strength?

Miquel A. Bru. At Genomcore, we work to implement precision medicine in the real world. That means making precision medicine more accessible, efficient, and secure at the primary care level to enable its use in secondary care.

Our main strength lies in having developed our own technology platform—secure, interoperable, and fully compliant with European standards—that allows hospitals, laboratories, pharmaceutical companies, and public institutions to manage and interpret complex biomedical data with complete safety and regulatory compliance.
We combine deep expertise in bioinformatics, omics sciences, and digital health with a clear vision: turning data into useful, scalable, and sustainable clinical decisions.

AseBio. What does AseBio mean to you?

Miquel A. Bru. For us, AseBio represents the meeting point of Spain’s biotechnology ecosystem: a space for collaboration, innovation, and visibility for the sector. It’s a strategic community that aligns shared interests and strengthens biotechnology’s transformative role in the economy and society.

AseBio. When did you first hear about AseBio?

Miquel A. Bru. We’ve known about AseBio for years as a benchmark in the Spanish biotech sector, especially for its institutional representation, its annual report, and initiatives like BioSpain. Since the start of our activity, we’ve followed their work closely, and this year we’ve decided to take a step further by joining as active members.

AseBio. What do you hope to gain from being part of an association like AseBio?

Miquel A. Bru. We hope to share knowledge, create synergies with other members, and contribute to driving innovation in the health sector through our expertise in managing multimodal health data and precision medicine.
We’re also interested in participating in forums on regulation, digitalization, and technology transfer, key areas for the future of biotechnology in Europe.

AseBio. What is the biggest challenge facing the biotech sector or your company?

Miquel A. Bru. One of the major challenges in biotech is turning the growing volume of biomedical data into real value for clinical practice.

At Genomcore, we’re working to close that gap: integrating omics data effectively and securely into clinical practice. To do this, we created and are constantly developing GENOMCORE BIMS, a digital platform that enables interoperability, traceability, data structuring, and analysis—just as we’re already doing in flagship projects like SISGENES (Spanish Ministry of Health) or the genomic programs of OSAKIDETZA and CATSALUT.

Moving toward a common, ethical, and scalable digital infrastructure is not just a technical challenge, it’s a necessary condition for biotechnology to fulfill its transformative promise in healthcare.